Home › Research › Topics › cerebrospinal
cerebrospinal
834 studies tagged cerebrospinal, dated 1980-07-01 to 2026-10-16. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
834 studies carry this tag.
Date range
1980 to 2026
Top journals
- Neurology 131
- Alzheimer s & Dementia 37
- JAMA neurology 35
- Alzheimer's research & therapy 28
- Archives of neurology 25
247 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Biomarkers in cerebrospinal fluid (CSF) are being used increasingly to diagnose early Alzheimer's disease (AD).
-
These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD.
-
A slower rate of hippocampal atrophy in normal APOE2 carriers is consistent with the lower risk of Alzheimer disease in these individuals.
-
Cognitive impairment is prevalent in older schizophrenia patients but its biological basis is unknown.
-
The existence of an effective biomarker for early detection of Alzheimer disease would facilitate improved diagnosis and stimulate therapeutic trials.
-
Low cerebrospinal fluid (CSF) amyloid-beta(1-42) concentration and high total-tau/Abeta(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer's disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials (Shaw et al, Ann Neurol 2009;65:403-13; Dubois et al, Lancet Neurol 2007;6:734-46).
-
Cognitive decline associated with Parkinson disease (PD) is common and highly disabling.
-
We investigated whether blood N-glycan changes can be used as a diagnostic biomarker for Alzheimer disease (AD).
-
51/100
Alzheimer's Disease Neuroimaging Initiative database.
-
These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
-
In common forms of Alzheimer disease (AD), anterograde memory impairment is the first deficit to occur.
-
Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.
-
Clinical trials of disease modifying drugs for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) might benefit from enrichment with true AD cases.
-
Immunoassays of total tau (t-tau), tau phosphorylated at threonine 181 (p-tau(181)), and beta-amyloid 1-42 (Abeta(42)) concentrations were performed in CSF obtained from participants in the Alzheimer's Disease Neuroimaging Initiative.
-
A subgroup of patients with Alzheimer disease with extreme levels of CSF biomarkers exhibits worse clinical outcomes over time, including faster progression of cognitive deficits, no response to ChEI treatment, and a higher mortality.
-
Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD).
-
Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease.
-
Brain atrophy and altered CSF levels of amyloid beta (Abeta(42)) and the microtubule-associated protein tau are potent biomarkers of Alzheimer's disease (AD)-related pathology.
-
Alzheimer's disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention.
-
Disease modifying drugs for Alzheimer's disease (AD) are likely to be most effective when given in non-demented subjects.
-
Inflammation is believed to play a role in Alzheimer's disease (AD).
-
This study proposes a model that relates disease stages to Alzheimer's disease biomarkers.
-
56/100
Patients with dementia were older and had higher rates of hypertension, coronary artery disease, renal failure, heart failure, and prior strokes.
-
Clinical, cognitive, and CSF markers consistent with AD may precede detection of cerebral amyloid beta using amyloid imaging agents such as PiB that primarily label fibrillar amyloid beta plaques.
-
58/100
Circulating leptin was associated with a reduced incidence of dementia and AD and with cerebral brain volume in asymptomatic older adults.
-
Mild cognitive impairment (MCI) is a nosological entity proposed as an intermediate state between normal aging and dementia.
-
HIV-associated neurologic disorders (HAND) continue to develop in many patients with HIV.
-
The human GFAP splice variants GFAPDelta164 and GFAPDeltaexon6 both result in a GFAP protein isoform with a unique out-of-frame carboxy-terminus that can be detected by the GFAP+1 antibody.
-
We have used these markers and evaluated their performance.
-
CSF biomarkers amyloid beta 1-42 (Abeta(42)), total tau (tau), and tau phosphorylated at threonine 181 (p-tau-181) are useful diagnostic markers for Alzheimer disease (AD).
-
Alzheimer's disease (AD) is the leading cause of dementia.
-
Microbleeds (MBs) are commonly observed in Alzheimer disease.
-
The purpose of this study was to investigate the potential relationships between cerebrospinal fluid (CSF) measurements of beta-amyloid-1-42 (Abeta(1-42)) and total tau to (11)C-Pittsburgh compound B ((11)C-PiB) and 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ((18)F-FDDNP) binding as measured using PET.
-
The AD subjects showed positive correlations between CSF-T-tau and CSF-P-tau versus CSF-Mn (r(s) = 0.22, p = 0.004; r(s) = 0.18, p = 0.021).
-
Cerebral amyloid angiopathy is caused by deposition of the amyloid beta protein in the cerebral vasculature.
-
During follow-up, 271 participants with MCI were diagnosed with AD and 59 with other dementias.
-
We found no significant correlation between CSF biomarkers and cognitive scores in any of the 3 clinical groups individually.
-
MRI and CSF provide complimentary predictive information about time to conversion from amnestic mild cognitive impairment to Alzheimer disease and combination of the 2 provides better prediction than either source alone.
-
The CSF AD profile was more common in patients with SCI (31 of 60 [52%]), naMCI (25 of 37 [68%]), and aMCI (56 of 71 [79%]) than in healthy controls (28 of 89 [31%]).
-
In a population-based sample, increasing gliosis precedes development of Alzheimer lesions.
-
Cerebrospinal fluid (CSF) levels of Abeta peptide 1-42 (Abeta 42), tau, and phosphorylated tau (ptau) are potential biomarkers of Alzheimer disease.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with characteristic neuropathological changes of the brain.
-
67/100
CSF A beta(1-42) was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%.
-
There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD).
-
Clusters of CSF biomarker levels are related to cognitive profiles in Alzheimer disease.
-
33/100
In recent studies, patients diagnosed with Alzheimer's disease (AD) showed significantly elevated CSF levels of tau protein.
-
The association of alpha-synuclein (alpha-syn) neuropathology with Parkinson's disease (PD) and several related disorders has led to an intense research effort to develop cerebrospinal fluid (CSF)- or blood-based alpha-syn biomarkers for these types of diseases.
-
A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer's disease (AD).
-
These results suggest that neuronal injury markers such as VLP-1 may have utility as biomarkers for AD.
-
Mild cognitive impairment (MCI) is regarded as the prodromal stage of dementia disorders, such as Alzheimer's disease (AD).
From across this tag
10 of the 829 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country
- Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers
- Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
- Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults
- Proteomic analysis of host brain components that bind to infectious particles in Creutzfeldt-Jakob disease
- Aβ positive, tau biomarker negative cognitive impairment is associated with significant non‐Alzheimer's disease neuropathologies
- Plasma Biomarker Association with Cognition in Uganda
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
- Current state of Alzheimer's fluid biomarkers
- CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases